Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q8IUG5
UPID:
MY18B_HUMAN
Alternative names:
-
Alternative UPACC:
Q8IUG5; A0A075B6F5; B2RWP3; F5GXR6; F5GYU7; Q8NDI8; Q8TE65; Q8WWS0; Q96KH2; Q96KR8; Q96KR9
Background:
Unconventional myosin-XVIIIb plays a pivotal role in intracellular trafficking within muscle cells and regulates muscle-specific genes. Its presence in the nucleus and cytoplasm suggests a dynamic function in muscle cell biology and tumor suppression, particularly in lung cancer where its expression inhibits uncontrolled cell growth.
Therapeutic significance:
Linked to Klippel-Feil syndrome 4, characterized by skeletal abnormalities and myopathy, Unconventional myosin-XVIIIb's genetic variants highlight its clinical importance. Understanding its role could open doors to potential therapeutic strategies for skeletal disorders and cancer.